German health minister says vaccine progress very encouraging

German Health Minister Jens Spahn has described the announcement of a promising experimental vaccine developed by the Mainz-based BioNTech and U.S. pharma giant Pfizer as `very encouraging.’

Spahn said that an initial analysis of phase 3 clinical trial data showed that “the vaccine makes a difference’’.

He said that a German company was among the first developers of a viable drug to prevent COVID-19.

ALSO READ: 30 herbal medicine hawkers arrested in Kano for using vulgar words

“This does not mean that approval will come tomorrow,’’ he cautioned.

BioNTech and Pfizer announced that their vaccine candidate is 90 per cent effective in preventing COVID-19 and that they planned to apply for emergency authorisation with the United States’ FDA regulator next week.

(NAN)

 

YOU SHOULD NOT MISS THESE HEADLINES FROM NIGERIAN TRIBUNE

The All Progressives Congress (APC) has told a Federal High Court in Abuja, that the Comrade Adams Oshiomhole-led National Working Committee (NWC) was sacked to solve the internal leadership crises rocking the party.

The party also said that immediately the Caretaker/Extraordinary Convention Planning Committee was put in place after the NWC’s dissolution, the crises that had characterised its affairs were laid to rest.

Post COVID-19: Kano based industrialist tasks FG on economy 

A Kano based industrialist, Chief Kalu Ogbonnaya, has advised the Federal Government to take necessary steps to stimulate the nation’s economy to prevent a recession post COVID-19.

Ogbonnaya who spoke in an interview with the News Agency of Nigeria (NAN) on Thursday in Kano, said as a result of the coronavirus raving the world, no business has been moving.

Constitution amendment: Send your position to the committee, Senate replies NEF

The Senate on Monday responded to the claim by the Northern Elders Forum that the proposed amendment of the 1999 Constitution was needless.

You might also like
Comments

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More